Titan Pharmaceuticals, Inc.
TTNP
$4.99
$0.091.84%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | 0.00 | 4.00K |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | 0.00 | 4.00K |
Cost of Revenue | -- | -- | -- | 487.00K | 911.00K |
Gross Profit | -- | -- | -- | -487.00K | -907.00K |
SG&A Expenses | 2.61M | 4.03M | 4.56M | 5.34M | 6.22M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 2.61M | 4.03M | 4.56M | 5.82M | 7.13M |
Operating Income | -2.61M | -4.03M | -4.56M | -5.82M | -7.13M |
Income Before Tax | -2.81M | -4.21M | -4.71M | -5.89M | -5.46M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -2.81 | -4.21 | -4.71 | -5.89 | -5.46 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -2.81M | -4.21M | -4.71M | -5.89M | -5.46M |
EBIT | -2.61M | -4.03M | -4.56M | -5.82M | -7.13M |
EBITDA | -2.61M | -4.02M | -4.55M | -5.81M | -7.09M |
EPS Basic | -2.96 | -4.61 | -5.23 | -6.98 | -6.59 |
Normalized Basic EPS | -1.85 | -2.88 | -3.27 | -4.38 | -5.58 |
EPS Diluted | -2.96 | -4.61 | -5.23 | -6.98 | -6.59 |
Normalized Diluted EPS | -1.85 | -2.88 | -3.27 | -4.38 | -5.58 |
Average Basic Shares Outstanding | 3.81M | 3.66M | 3.60M | 3.44M | 3.27M |
Average Diluted Shares Outstanding | 3.81M | 3.66M | 3.60M | 3.44M | 3.27M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |